Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 14 Squamous Cell Carcinoma of Head and Neck 12 Colorectal Neoplasms 11 Carcinoma, Non-Small-Cell Lung 10 Breast Neoplasms 10 Carcinoma, Renal Cell 7 Prostatic Neoplasms 6 Head and Neck Neoplasms 6 Diabetes Mellitus, Insulin-Dependent, 12 6 Neoplasms 5 Lung Neoplasms 5 Biliary Tract Neoplasms 5 Small Cell Lung Carcinoma 4 Ovarian Neoplasms 4 Uterine Cervical Neoplasms 3 Urinary Bladder Neoplasms 3 Recurrence 3 Pancreatic Neoplasms 3 Neoplasm Metastasis 3 Fallopian Tube Neoplasms 3 Cholangiocarcinoma 3 Carcinoma, Hepatocellular 3 Advanced Solid Tumors 3 Stomach Neoplasms 2 Sarcoma 2 Recurrent Squamous Cell Lung Carcinoma 2 Liver Neoplasms 2 Kidney Neoplasms 2 Gallbladder Neoplasms 2 Esophageal Squamous Cell Carcinoma 2

Interventions

tremelimumab 1 durvalumab 1 Sodium Chloride 1 Radiotherapy 1 Lidocaine 1 Hyperthermic Intraperitoneal Chemotherapy 1 Cystectomy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Invasive Bladder Cancer × tremelimumab × Clear all

NCT03702179 2024-12-05

IMMUNOPRESERVE

Spanish Oncology Genito-Urinary Group

Phase 2 Completed

32 enrolled 19 charts

Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡